AlzeCure Pharma AB (ALZCUR.ST)
AlzeCure Pharma AB operates in the Biotechnology industry of the Healthcare sector, headquartered in Huddinge, AB, SE. The stock last traded at $7.50, down 0.79% on the session, giving a market capitalisation of $984.6M. Its beta of -0.09 implies it has historically moved less than the broad market.
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
AlzeCure Pharma AB is most often compared with the following Healthcare names: